Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy

D. Száraz, V. Peřina, J. Treglerová, C. Macháček, O. Zendulka, P. Bořilová Linhartová

. 2024 ; 5 (-) : 1473049. [pub] 20241204

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25001989

Both denosumab (DMB) and bisphosphonates (BPs), antiresorptive drugs (ARDs) used for the treatment of osteoporosis and oncological disorders, are known for their potential to cause medication-related osteonecrosis of the jaws (MRONJ). Besides ARDs, statins were recently associated with MRONJ development, especially in patients taking higher doses of statins for a longer period of time. Here, we report a case of a female patient with osteoporosis using statins and treated with alendronate for 3 years who rapidly developed MRONJ stage III after only a single low dose of DMB. After partial maxillectomy complete healing was observed without any recurrence. We performed a literature review of cases with MRONJ triggered by a single low dose of DMB, with or without previous application of other ARDs. Only six similar cases of patients who developed MRONJ after a single low dose of DMB following previous BP therapy have been reported so far. Besides these, literature reports one patient who developed MRONJ after a single dose of DMB following romosozumab treatment and five cases developing MRONJ after a single dose of DMB even without any previous ARD treatment. We suggest that before DMB therapy is initiated, all factors predisposing to MRONJ development should be considered.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25001989
003      
CZ-PrNML
005      
20250123101941.0
007      
ta
008      
250117e20241204sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/froh.2024.1473049 $2 doi
035    __
$a (PubMed)39697786
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Száraz, Dávid $u Clinic of Maxillofacial Surgery, University Hospital Brno, Brno, Czechia $u Clinic of Maxillofacial Surgery, Faculty of Medicine, Masaryk University, Brno, Czechia
245    10
$a Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy / $c D. Száraz, V. Peřina, J. Treglerová, C. Macháček, O. Zendulka, P. Bořilová Linhartová
520    9_
$a Both denosumab (DMB) and bisphosphonates (BPs), antiresorptive drugs (ARDs) used for the treatment of osteoporosis and oncological disorders, are known for their potential to cause medication-related osteonecrosis of the jaws (MRONJ). Besides ARDs, statins were recently associated with MRONJ development, especially in patients taking higher doses of statins for a longer period of time. Here, we report a case of a female patient with osteoporosis using statins and treated with alendronate for 3 years who rapidly developed MRONJ stage III after only a single low dose of DMB. After partial maxillectomy complete healing was observed without any recurrence. We performed a literature review of cases with MRONJ triggered by a single low dose of DMB, with or without previous application of other ARDs. Only six similar cases of patients who developed MRONJ after a single low dose of DMB following previous BP therapy have been reported so far. Besides these, literature reports one patient who developed MRONJ after a single dose of DMB following romosozumab treatment and five cases developing MRONJ after a single dose of DMB even without any previous ARD treatment. We suggest that before DMB therapy is initiated, all factors predisposing to MRONJ development should be considered.
590    __
$a NEINDEXOVÁNO
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Peřina, Vojtěch $u Clinic of Maxillofacial Surgery, University Hospital Brno, Brno, Czechia $u Clinic of Maxillofacial Surgery, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Treglerová, Jana $u Clinic of Maxillofacial Surgery, University Hospital Brno, Brno, Czechia $u Clinic of Maxillofacial Surgery, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Macháček, Ctirad $u Department of Pathology, University Hospital Brno, Brno, Czechia $u Department of Pathology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Zendulka, Ondřej $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Bořilová Linhartová, Petra $u Clinic of Maxillofacial Surgery, University Hospital Brno, Brno, Czechia $u RECETOX, Faculty of Science, Masaryk University, Brno, Czechia
773    0_
$w MED00209099 $t Frontiers in oral health $x 2673-4842 $g Roč. 5 (20241204), s. 1473049
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39697786 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101935 $b ABA008
999    __
$a ok $b bmc $g 2254436 $s 1237992
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 5 $c - $d 1473049 $e 20241204 $i 2673-4842 $m Frontiers in oral health $n Front Oral Health $x MED00209099
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace